title: The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response.
abstract: The discovery of a pharmacological treatment for phenylketonuria (PKU) raised new questions about function and dysfunction of phenylalanine hydroxylase (PAH), the enzyme deficient in this disease. To investigate the interdependence of the genotype, the metabolic state (phenylalanine substrate) and treatment (BH(4) cofactor) in the context of enzyme function in vitro and in vivo, we (i) used a fluorescence-based method for fast enzyme kinetic analyses at an expanded range of phenylalanine and BH(4) concentrations, (ii) depicted PAH function as activity landscapes, (iii) retraced the analyses in eukaryotic cells, and (iv) translated this into the human system by analyzing the outcome of oral BH(4) loading tests. PAH activity landscapes uncovered the optimal working range of recombinant wild-type PAH and provided new insights into PAH kinetics. They demonstrated how mutations might alter enzyme function in the space of varying substrate and cofactor concentrations. Experiments in eukaryotic cells revealed that the availability of the active PAH enzyme depends on the phenylalanine-to-BH(4) ratio. Finally, evaluation of data from BH(4) loading tests indicated that the patient's genotype influences the impact of the metabolic state on drug response. The results allowed for visualization and a better understanding of PAH function in the physiological and pathological state as well as in the therapeutic context of cofactor treatment. Moreover, our data underscore the need for more personalized procedures to safely identify and treat patients with BH(4)-responsive PAH deficiency.
authors.affiliation: Department of Molecular Pediatrics, Dr von Hauner Children’s Hospital, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Staudigl
authors.forename: Søren W
authors.initials: SW
authors.lastname: Gersting
authors.forename: Marta K
authors.initials: MK
authors.lastname: Danecka
authors.forename: Dunja D
authors.initials: DD
authors.lastname: Messing
authors.forename: Mathias
authors.initials: M
authors.lastname: Woidy
authors.forename: Daniel
authors.initials: D
authors.lastname: Pinkas
authors.forename: Kristina F
authors.initials: KF
authors.lastname: Kemter
authors.forename: Nenad
authors.initials: N
authors.lastname: Blau
authors.forename: Ania C
authors.initials: AC
authors.lastname: Muntau
mesh_terms: D001708:Biopterins / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D003067:Coenzymes / Q000494:pharmacology / Q000627:therapeutic use*; D004789:Enzyme Activation / Q000187:drug effects; D005838:Genotype; D057809:HEK293 Cells; D006801:Humans; D007700:Kinetics; D018832:Molecular Chaperones / Q000378:metabolism; D009154:Mutation / Q000235:genetics; D010649:Phenylalanine / Q000378:metabolism*; D010651:Phenylalanine Hydroxylase / Q000172:deficiency / Q000235:genetics* / Q000378:metabolism*; D010661:Phenylketonurias / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics
chemical_list: D003067:Coenzymes; D018832:Molecular Chaperones; D001708:Biopterins; D010649:Phenylalanine; D010651:Phenylalanine Hydroxylase; C003402:sapropterin